For instance, lapatinib, a TKI that simultaneously inhibits HER2 and EGFR and had shown efficacy in breast cancer, failed to demonstrate improved overall survival when combined with chemotherapy in gastric cancer, as shown in the LOGIC study and the TyTAN study targeting Asian patients [8,9]. This evidence concerns the gene ERBB2 and breast carcinoma.